Disc Medicine (IRON) Common Equity (2020 - 2026)

Disc Medicine (IRON) has reported Common Equity for 7 consecutive years, with $644.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Common Equity rose 4.88% year-over-year to $644.2 million; the TTM figure through Jun 2026 stood at $644.2 million (up 4.88% YoY), while the FY2025 annual figure was $739.8 million, up 66.78% from the prior year.
• Common Equity retreated to $644.2 million in Q2 2026 per IRON's latest filing, from $688.4 million in the prior quarter.
• Across five years, Common Equity topped out at $739.8 million in Q4 2025 and bottomed at -$98.5 million in Q3 2022.
• Historically, Common Equity has averaged $382.7 million across 5 years, with a median of $407.4 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity plunged 169.95% — and 2023, when it surged 548.44%.
• Disc Medicine's Common Equity stood at $176.6 million in 2022, then surged by 95.43% to $345.1 million in 2023, then advanced by 28.53% to $443.6 million in 2024, then soared by 66.78% to $739.8 million in 2025, then declined by 12.93% to $644.2 million in 2026.
• Business Quant data shows IRON's Common Equity at $644.2 million in Q2 2026, $688.4 million in Q1 2026, and $739.8 million in Q4 2025.